Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Van Cutsem

Showing results (131-140 of 499) with videos related to

Pageof 50
Sort By:
Acta Chirurgica Belgica|October 28, 2016
Hepatic radiation injury mimicking metastasis in distal esophageal cancer<sup></sup>Karel Demey, Hans Van Veer, Philippe Nafteux, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2005
Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?Fabio Efficace, Andrew Bottomley, Corneel Coens, et al.
Anti-Cancer Drugs|November 28, 2017
Integrated safety summary for trifluridine/tipiracil (TAS-102)Alfredo Falcone, Atsushi Ohtsu, Eric Van Cutsem, et al.
Future Oncology (London, England)|September 13, 2019
A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreasPhilip A Philip, Marc E Buyse, Angela T Alistar, et al.
Clinical Nuclear Medicine|November 12, 2013
Influence of time delay on the estimated lung shunt fraction on 99mTc-labeled MAA scintigraphy for 90Y microsphere treatment planningRuth De Gersem, Geert Maleux, Hubert Vanbilloen, et al.
Cancers|January 11, 2022
Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization StrategiesNiloefar Ahmadi Bidakhvidi, Karolien Goffin, Jeroen Dekervel, et al.
BMC Cancer|April 10, 2024
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 studyElena Elez, Antonio Cubillo, Pilar Garcia Alfonso, et al.
Cancer|February 4, 2009
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapyMarc Peeters, Salvatore Siena, Eric Van Cutsem, et al.
Current Medical Research and Opinion|October 17, 2023
Tislelizumab in advanced/metastatic esophageal squamous cell carcinoma: health-related quality of life in Asian patientsSung-Bae Kim, Eric Van Cutsem, Jaffer Ajani, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2018
Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 studyGertraud Stocker, Ulrich T Hacker, Frédéric Fiteni, et al.
Pageof 50

Showing results (131-140 of 499) with videos related to

Sort By:
Pageof 50
Acta Chirurgica Belgica|October 28, 2016
Hepatic radiation injury mimicking metastasis in distal esophageal cancer<sup></sup>Karel Demey, Hans Van Veer, Philippe Nafteux, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2005
Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?Fabio Efficace, Andrew Bottomley, Corneel Coens, et al.
Anti-Cancer Drugs|November 28, 2017
Integrated safety summary for trifluridine/tipiracil (TAS-102)Alfredo Falcone, Atsushi Ohtsu, Eric Van Cutsem, et al.
Future Oncology (London, England)|September 13, 2019
A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreasPhilip A Philip, Marc E Buyse, Angela T Alistar, et al.
Clinical Nuclear Medicine|November 12, 2013
Influence of time delay on the estimated lung shunt fraction on 99mTc-labeled MAA scintigraphy for 90Y microsphere treatment planningRuth De Gersem, Geert Maleux, Hubert Vanbilloen, et al.
Cancers|January 11, 2022
Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization StrategiesNiloefar Ahmadi Bidakhvidi, Karolien Goffin, Jeroen Dekervel, et al.
BMC Cancer|April 10, 2024
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 studyElena Elez, Antonio Cubillo, Pilar Garcia Alfonso, et al.
Cancer|February 4, 2009
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapyMarc Peeters, Salvatore Siena, Eric Van Cutsem, et al.
Current Medical Research and Opinion|October 17, 2023
Tislelizumab in advanced/metastatic esophageal squamous cell carcinoma: health-related quality of life in Asian patientsSung-Bae Kim, Eric Van Cutsem, Jaffer Ajani, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2018
Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 studyGertraud Stocker, Ulrich T Hacker, Frédéric Fiteni, et al.
Pageof 50